BOK Financial Reports Record Earnings for Second Straight Quarter
$142 million or $2.00 Per Share in the Third QuarterTULSA, Okla., Oct. 23, 2019 (GLOBE NEWSWIRE) — BOK Financial (NASDAQ: […]
TSX News -
ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
TORONTO and CAMBRIDGE, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company […]
Brink’s Reports Third-Quarter Results
Strong Results in North and South America More Than Offset Increased Currency Headwinds2019 Guidance Adjusted for Expected Full-Year Impact of […]
U.S. Patent Allowed Covering Acuitas Lighthouse® Software
GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN) announced today that the United States Patent and […]
Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) — Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today […]
FirstService Reports Strong Third Quarter Operating Results
Revenue and Profitability Driven by 8% Organic Growth and Global Restoration AcquisitionOperating highlights:TORONTO, Oct. 23, 2019 (GLOBE NEWSWIRE) — FirstService […]
First National Corporation Announces Third Quarter Earnings
STRASBURG, Va., Oct. 23, 2019 (GLOBE NEWSWIRE) — First National Corporation (the “Company” or “First National”) (NASDAQ:FXNC) reported net income […]
Allot to Host Third Quarter 2019 Earnings Results Conference Call on November 5, 2019
Hod Hasharon, Israel, Oct. 23, 2019 (GLOBE NEWSWIRE) — Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of […]
VSBLTY GROUPE TECHNOLOGIES ANNOUNCES CLOSING OF THIRD AND FINAL TRANCHE OF BROKERED PRIVATE PLACEMENT LED BY ECHELON WEALTH PARTNERS
PHILADELPHIA, PA, Oct. 23, 2019 (GLOBE NEWSWIRE) — Further to its news releases on August 13, 2019, August 29, 2019 […]
Axovant Presents First Evidence of Clinical Stabilization in Tay-Sachs Disease at the European Society of Gene and Cell Therapy 27th Annual Congress
Initial data with AXO-AAV-GM2 suggests stabilization of disease course, attainment of normal developmental milestones, and improvement in myelination on brain […]
